The use of hepatitis B immunoglobulin in the Netherlands

H. W. Reesink; W. J. Duimel; J. E. de Boer; E. H. van Elven; H. G. Brummelhuis

The use of hepatitis B immunoglobulin in the Netherlands

H. W. Reesink
, W. J. Duimel
, J. E. de Boer
, E. H. van Elven
, H. G. Brummelhuis

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Hepatitis B immunoglobulin (HBIg) was administered to 241 patients contaminated with HBAg positive material; 116 persons were followed up for 7 months after the HBIg injection. Only 4 (3.4%) cases of hepatitis B with jaundice and demonstrable HBAg occurred and 15 (12.9%) cases of subclinical hepatitis B were observed. HBIg is well tolerated. Passively transferred HBAb were demonstrable for 2-3 months and no chronic carriers of HBAg were seen after administration of HBIg

Original language	English
Pages (from-to)	310-315
Journal	Developments in biological standardization
Volume	30
Publication status	Published - 1975

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{67f114c5b95d430b8cb86f8b25144620,

title = "The use of hepatitis B immunoglobulin in the Netherlands",

abstract = "Hepatitis B immunoglobulin (HBIg) was administered to 241 patients contaminated with HBAg positive material; 116 persons were followed up for 7 months after the HBIg injection. Only 4 (3.4\%) cases of hepatitis B with jaundice and demonstrable HBAg occurred and 15 (12.9\%) cases of subclinical hepatitis B were observed. HBIg is well tolerated. Passively transferred HBAb were demonstrable for 2-3 months and no chronic carriers of HBAg were seen after administration of HBIg",

author = "Reesink, \{H. W.\} and Duimel, \{W. J.\} and \{de Boer\}, \{J. E.\} and \{van Elven\}, \{E. H.\} and Brummelhuis, \{H. G.\}",

year = "1975",

language = "English",

volume = "30",

pages = "310--315",

journal = "Developments in biological standardization",

issn = "0301-5149",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - The use of hepatitis B immunoglobulin in the Netherlands

AU - Reesink, H. W.

AU - Duimel, W. J.

AU - de Boer, J. E.

AU - van Elven, E. H.

AU - Brummelhuis, H. G.

PY - 1975

Y1 - 1975

N2 - Hepatitis B immunoglobulin (HBIg) was administered to 241 patients contaminated with HBAg positive material; 116 persons were followed up for 7 months after the HBIg injection. Only 4 (3.4%) cases of hepatitis B with jaundice and demonstrable HBAg occurred and 15 (12.9%) cases of subclinical hepatitis B were observed. HBIg is well tolerated. Passively transferred HBAb were demonstrable for 2-3 months and no chronic carriers of HBAg were seen after administration of HBIg

AB - Hepatitis B immunoglobulin (HBIg) was administered to 241 patients contaminated with HBAg positive material; 116 persons were followed up for 7 months after the HBIg injection. Only 4 (3.4%) cases of hepatitis B with jaundice and demonstrable HBAg occurred and 15 (12.9%) cases of subclinical hepatitis B were observed. HBIg is well tolerated. Passively transferred HBAb were demonstrable for 2-3 months and no chronic carriers of HBAg were seen after administration of HBIg

M3 - Article

C2 - 54274

SN - 0301-5149

VL - 30

SP - 310

EP - 315

JO - Developments in biological standardization

JF - Developments in biological standardization

ER -

The use of hepatitis B immunoglobulin in the Netherlands

Abstract

UN SDGs

Fingerprint

Cite this